Compare BLKB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | GH |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 14.1B |
| IPO Year | 2004 | 2018 |
| Metric | BLKB | GH |
|---|---|---|
| Price | $64.28 | $103.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 21 |
| Target Price | $70.50 | ★ $96.48 |
| AVG Volume (30 Days) | 341.2K | ★ 1.8M |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,136,093,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.00 |
| Revenue Next Year | $4.00 | $26.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $54.56 | $29.91 |
| 52 Week High | $81.39 | $112.43 |
| Indicator | BLKB | GH |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 57.55 |
| Support Level | $62.57 | $96.28 |
| Resistance Level | $64.84 | $103.17 |
| Average True Range (ATR) | 1.72 | 3.53 |
| MACD | 0.21 | -0.70 |
| Stochastic Oscillator | 84.38 | 71.98 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.